The scene
A clinician likes the product. The founder leaves the meeting encouraged. Then the next question appears: who pays, what budget owns it, and what value can be measured?
That is where a clinical story needs an economic-buyer brief. The brief does not try to prove payment or purchasing authority. It shows which buyer question is open, which source supports the current wording, and which assumption needs review before price becomes the only conversation.
The wrong frame
The wrong frame is assuming that clinical interest automatically creates purchasing permission. In many device conversations, clinical, operational, budget, and reimbursement questions travel through different people.
A founder who treats those questions as one decision usually discovers the gap late. A better brief names the gap early: the clinician's reason to care, the operating leader's reason to change, the budget owner's reason to fund, and the reimbursement or payment uncertainty that should not be hidden.
Source ledger for the brief
The source ledger should stay narrow. CMS sources can explain Medicare coverage-determination concepts. FDA sources can identify some public device authorization, clearance, approval, and database context. Neither source should be used as a shortcut to a customer-specific payment or purchasing conclusion.
For each claim, the founder should write what the source can tell, what it cannot decide, and who owns the next decision. That prevents the sales story from sounding stronger than the evidence.
- Coverage source: what CMS or payer-facing public material actually says.
- Product status source: what FDA public material can show about the device record.
- Customer source: what the hospital, clinic, distributor, or buyer still needs to validate.
- Open question: what must be reviewed before pricing, reimbursement, or budget approval is discussed as fact.
Build the economic-buyer brief
- Clinical user value: what improves for the user or patient workflow.
- Operational value: what changes in time, burden, throughput, support, or risk handling.
- Budget owner: who absorbs cost or approves the purchase.
- Reimbursement status: what is known, unknown, or out of scope.
- Pilot-value plan: what evidence the customer could review after limited use.
Economic-buyer worksheet
| Question | Owner | Evidence to prepare |
|---|---|---|
| Who feels the clinical problem? | Clinical user | Use case, workflow burden, and current alternative. |
| Who pays or approves? | Budget owner | Department, capital/operating budget path, and approval timing. |
| What reimbursement question appears? | Reimbursement or payer reviewer | Known codes, coverage uncertainty, and source limits. |
| What operational proof is needed? | Operations owner | Training, support, throughput, staffing, and adoption-risk measures. |
| What should the pilot measure? | Founder and customer sponsor | A small set of measurable review points, not a guaranteed return-on-investment claim. |
The founder-level move
Do not wait until price pressure starts. Prepare the economic story next to the clinical story so the next stakeholder does not have to invent the value logic.
The useful output is a brief the founder can bring into a buyer conversation without overclaiming. It should make the next review easier: source notes on one side, buyer assumptions on the other, and explicit open questions for qualified review.
Source ledger
What it can tell you
Centers for Medicare & Medicaid Services (CMS) explains national and local coverage determination concepts for Medicare.
What it cannot decide
Whether a specific device, use case, customer, payer, or purchase will be covered, reimbursed, or economically attractive.
What it can tell you
FDA public sources can show certain clearance, approval, authorization, or database information for medical devices.
What it cannot decide
Reimbursement, customer budget, pricing, purchasing, payment, or return-on-investment logic.
Frequently asked questions
Does this determine reimbursement?
No. This prepares questions and separates assumptions. It does not determine coverage, coding, payment, reimbursement, or economic value for any specific device or customer.
What is the first useful output?
A one-page economic-buyer brief: clinical value, operational value, budget owner, reimbursement uncertainty, pilot-value measurement, and open review questions.
Can FDA status answer a pricing question?
No. FDA public status and customer pricing logic are different questions. The brief can place FDA source notes next to the buyer story, but it does not determine price, payment, budget approval, or purchasing outcome.
When should reimbursement uncertainty be raised?
Before the buyer asks for a price-only answer. The brief should name what is known, what is unknown, and which qualified reviewer or customer owner should validate the next step.
Need the economic-buyer story separated from the clinical story?
TrueMedDevice can prepare a first economic-buyer brief as part of a Market-Ready Sales & Support Pack.